Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive covers the latest trends and developments in biotech and pharma, from drug discovery and development to commercialization and marketing. Find news, data, deep dives and more on topics such as cancer, gene therapy, obesity, M&A and …
BridgeBio sends rare disease drugs to new company
WEBAug 21, 2024 · BridgeBio Pharma has transferred several preclinical and early clinical-stage drugs to GondolaBio, a new company backed by $300 million in funding from investors. GondolaBio will focus on rare diseases such as erythropoietic protoporphyria, alpha-1 antitrypsin deficiency and tuberous sclerosis complex.
Chasing Novo and Lilly: The obesity drugs that could challenge …
WEBApr 30, 2024 · One study can start a pharmaceutical revolution. Four years ago, a large clinical trial run by Novo Nordisk showed a drug called semaglutide helped people with obesity lose, on average, around 15% of their weight.The results far exceeded what prior studies of other treatments had suggested was possible pharmaceutically, sparking a rush to research that has quickly reshaped the obesity drug field.
Investors put $400M into biotech licensing obesity drugs from China
WEBMay 16, 2024 · Bain Capital Life Sciences and other investors have put $400 million into Hercules CM NewCo, a startup that licensed three weight loss medicines from Jiangsu Hengrui Pharmaceuticals. The drugs are in various stages of clinical testing and target GLP-1 and GIP hormones.
Updated COVID shots from Pfizer, Moderna cleared by FDA
WEBAug 22, 2024 · Dive Brief: The Food and Drug Administration on Thursday cleared new versions of Pfizer’s and Moderna’s COVID-19 vaccines that are designed to better match the coronavirus strains currently circulating in the U.S. ; Both of Pfizer’s and Moderna’s reformulated shots target the KP.2 virus strain, which was dominant in the spring and belongs to the broader JN.1 lineage.
Zealand, Arrowhead advance obesity drugs; Bluebird narrows …
WEBAug 16, 2024 · Arrowhead Pharmaceuticals is bringing into human testing two RNA-based medicines for obesity, the company said Wednesday. Arrowhead expects to begin clinical trials next year for two candidates dubbed ARO-INHBE and ARO-ALK7, both of which work differently than available drugs and have shown signs in preclinical testing of being able to suppress weight as well as preserve muscle mass.
The biopharma industry outlook on 2024: Guarded optimism for a …
WEBJan 16, 2024 · The biopharma sector faces a mix of challenges and opportunities in 2024, from new drugs for obesity and cancer to patent cliffs and FTC scrutiny. Read the latest news and analysis on the trends, deals and trials shaping the industry.
Merck pays $680M for struggling cancer biotech Harpoon
WEBJan 8, 2024 · Merck acquires Harpoon, a biotech developing bispecific antibodies for lung, abdominal and blood cancers. The deal aims to bolster Merck's pipeline of next-generation immunotherapies as Keytruda faces market competition.
CDC panel mulls changes to RSV vaccine recommendation
WEBMar 1, 2024 · Advisers to the Centers for Disease Control and Prevention are weighing updates to their recommendation older adults get vaccinated for respiratory syncytial virus, discussing changes at a meeting Thursday that would more forcefully encourage some individuals receive a shot.. At the meeting, the Advisory Committee on Immunization Practices reviewed safety and efficacy data on RSV vaccines sold ...
RA Capital-backed startup raises $100M; UCB sells China business
WEBAug 27, 2024 · Navigator Medicines, a biotech startup backed by RA Capital and Forbion, has secured a Series A round and in-licensed a bispecific antibody for autoimmune diseases. The company also appointed Dana McClintock as chief medical officer.